ALS Today Audio Podcasts

Steve Vucic PhD of Neuroscience Research Australia talks about transcranial magnetic stimulation (TMS), an emerging test that may help clinicians identify people with ALS before the first symptoms of disease. Learn more: http://blogs.als.net/post/2013/06/19/TMS-a-headstart-for-PALS.aspx

Paul Gordon MD of the Indian Health Service (HIS) talks about his latest results which suggest that ALS might be less common in Native Americans. His studies may one day help identify triggers of ALS and potential ways to fight the disease.

Kirsten Gruis MD of the State University of New York talks about the NeuRX DPS, a device that aims to help people with ALS breathe better and live longer by electrically conditioning the diaphragm. Learn more: http://blogs.als.net/post/2013/05/07/The-DPS-Point-Blank.aspx

Pierre-Francois Pradat MD PhD of the Assistance Publique - Hôpitaux de Paris in France talks about GSK's potential ALS medicine ozanezumab, now at phase II. Learn more: http://blogs.als.net/post/2013/04/09/A-Go-For-anti-NOGO-A.aspx

Steve Perrin PhD, CEO and CSO of ALS TDI, talks Gilenya, other emerging immunomodulators and their potential to treat ALS going forward. Read more: http://blogs.als.net/post/2013/02/12/Gilenya-giving-ALS-the-fingo.aspx

Michael Weiss MD, Director of the Neuromuscular Diseases Division of the University of Washington School of Medicine, discusses an upcoming phase II clinical trial that puts mexiletine to the test in ALS, a potential early treatment of the disease. Read more: http://blogs.als.net/post/2013/02/05/Mexiletine-channeling-ALS.aspx

Doug Kerr MD PhD, Biogen-Idec’s Director of Neurodegenerative Research, talks dexpramipexole, the lessons learned and the development of future ALS medicines in the clinic going forward. Read more: http://blogs.als.net/post/ALS-clinical-trials-powering-forward.aspx

Robert Miller MD, Director of California Pacific Medical Center’s Forbes Norris MDA/ALS Research and Treatment Center, talks NP001 and its potential to treat ALS going forward. Read more: http://blogs.als.net/post/2012/12/17/NP001-a-quiet-riot-in-ALS.aspx

Athanase Millogo, MD of Bobo-Dioulasso University Teaching Hospital in Burkina Faso, talks TROPALS and its potential impact on people with ALS/MND in Africa going forward. Read more: http://blogs.als.net/post/2012/11/06/ALS-Out-of-Africa.aspx

Jeff Rothstein MD PhD, director of the Packard Center for ALS Research at Johns Hopkins University School of Medicine, talks C9ORF72 and potential treatments for this form of ALS going forward. Read more: http://blogs.als.net/post/2012/10/29/ALS-dressed-to-the-C9s.aspx

Rick Bedlack MD PhD, Director of the Duke ALS Clinic in North Carolina, talks ALS clinical trials: where we are and where we need to go to develop better treatment strategies for the disease.

Klaus Nave PhD, Director of the Max Planck Institute of Experimental Medicine, discusses the emerging role of oligodendrocytes in ALS and potential treatment strategies going forward. Read more: http://blogs.als.net/post/2012/10/29/ALS-dressed-to-the-C9s.aspx

Rachael Marsden RN MSc, Clinical Care Coordinator at the Oxford MND Centre in England, did not know when she answered a help wanted ad that she would transform care and management of people with ALS in Turkey.

Athanase Millogo, MD of Bobo-Dioulasso University Teaching Hospital in Burkina Faso, hopes to make a difference for people with ALS beyond his nation's borders. Read more: http://blogs.als.net/post/2012/06/21/TROPALS-Circle-In-the-Sand.aspx

Guðjón Sigurðsson, pALS and ALS/MND International Alliance Chairman, talks about how he hopes to make life better for people with ALS in Iceland and elsewhere around the globe.

Akshay Anand PhD of the Postgraduate Institute of Medical Education and Research in Chandigarh, India, hopes to discover the secret behind the longevity of certain people with ALS/MND. Read more: http://blogs.als.net/post/2012/06/21/ALS-a-brief-history-of-more-time.aspx

Miriam Bucheli PhD of the Universidad San Francisco de Quito in Ecuador is on the hunt for environmental factors that might contribute to ALS including lead exposure. Read more: http://blogs.als.net/post/2012/07/05/Climb-every-mountain.aspx

Stanley Appel MD Director of the Methodist Neurological Institute in Texas, talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them. Read more: http://blogs.als.net/post/2011/12/16/Symphony-in-M.aspx